The Valley Desk

NCT04095858 · Interventional trial

Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)

Overall registry status Terminated

Phase 3

Conditions Acute Graft Versus Host Disease, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndromes

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov